Imperial College London
Mr Faruq Noormohamed

MrFaruqNoormohamed

Faculty of Medicine, Department of Surgery & Cancer

A
 
 
 
//

Contact

 

+44 (0)20 3315 8816f.noormohamed

 
 
//

Location

 

G3.47Chelsea and Westminster HospitalChelsea and Westminster Campus

//

Summary

 

Publications

Citation

BibTex format

@article{Noormohamed:1997:10.1111/j.1365-2125.1997.tb00042.x,
author = {Noormohamed, FH and Youle, MS and Higgs, CJ and Gazzard, BG and Lant, AF},
doi = {10.1111/j.1365-2125.1997.tb00042.x},
journal = {Br J Clin Pharmacol},
pages = {112--115},
title = {Renal excretion and pharmacokinetics of foscarnet in HIV sero-positive patients: effect of probenecid pretreatment.},
url = {http://dx.doi.org/10.1111/j.1365-2125.1997.tb00042.x},
volume = {43},
year = {1997}
}
Download

RIS format (EndNote, RefMan)

TY  - JOUR
AB  - AIMS: The present study was undertaken to test whether the anti-viral agent foscarnet undergoes significant tubular secretion, by using probenecid, an inhibitor of the organic acid secretory pathway in the proximal segment of the nephron. METHODS: The pharmacokinetics and renal excretion of foscarnet (90 mg kg-1 infused over 2 h) have been investigated, in the absence and presence of probenecid pretreatment (1 g twice daily for 3 days) in a group of 10 HIV seropositive patients. RESULTS: Mean (+/-s.d.) peak plasma concentrations were 904 +/- 65 microM (foscarnet) and 862 +/- 97 microM (foscarnet+probenecid) whilst the plasma AUC values were 3326 +/- 451 microM h and 3133 +/- 476 microM h respectively. Terminal elimination half-life remained unchanged at 5.6 +/- 0.7 h and the respective volumes of distribution at steady state were 23 +/- 31 (foscarnet) and 25 +/- 31 (foscarnet+probenecid). Mean total body clearance was 110 +/- 17 ml min-1 (foscarnet) and 113 +/- 13 ml min-1 (foscarnet+probenecid) and the corresponding renal clearances of foscarnet were 102 +/- 5 ml min-1 and 105 +/- 5 ml min-1 respectively. There were no significant differences in the total amount of foscarnet excreted by the kidney with 95 +/- 5% (foscarnet) and 91 +/- 6% (foscarnet+probenecid) of the intravenous dose excreted within 24 h. Glomerular filtration rates at 109 +/- 12 ml min-1 (foscarnet) and 100 +/- 13 ml min-1 (foscarnet+probenecid) and respective creatinine clearances at 120 +/- 15 and 119 +/- 10 ml min-1 remained unchanged throughout the study. CONCLUSIONS: The study shows that foscarnet is not transported via the probenecid-sensitive organic acid secretory pathway in the proximal tubule; the renal elimination of foscarnet is via glomerular filtration.
AU  - Noormohamed,FH
AU  - Youle,MS
AU  - Higgs,CJ
AU  - Gazzard,BG
AU  - Lant,AF
DO  - 10.1111/j.1365-2125.1997.tb00042.x
EP  - 115
PY  - 1997///
SN  - 0306-5251
SP  - 112
TI  - Renal excretion and pharmacokinetics of foscarnet in HIV sero-positive patients: effect of probenecid pretreatment.
T2  - Br J Clin Pharmacol
UR  - http://dx.doi.org/10.1111/j.1365-2125.1997.tb00042.x
UR  - https://www.ncbi.nlm.nih.gov/pubmed/9056062
VL  - 43
ER  -
Download